SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network is trending due to the launch of its V3 perpetuals on Ethereum Mainnet, alongside a widely discussed $1 million trading competition and a strategic shift to a deflationary token model with upcoming buybacks. The community is buzzing with both bullish excitement for this return to L1 derivatives infrastructure and caution regarding market volatility.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as community optimism grows around QNX's deepening integration into next-generation software-defined vehicles with key design wins like BMW's Neue Klasse and partnerships such as Alloy Kore with Vector, leading to expectations of accelerated revenue growth and strong Q3 earnings from its expanding automotive software portfolio.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following the FDA's approval of BYSANTI (milsaperidone) for Bipolar I Disorder and Schizophrenia, with market participants eagerly anticipating a significant re-rating of its valuation. The drug's New Chemical Entity (NCE) status and patent protection through 2044, combined with the potential of its GLP-1 nausea candidate, are fueling widespread community discussion about a possible near-term buyout.

Berachain

Berachain (BERA) is trending amid recent network upgrades like Bectra, new Proof-of-Liquidity reward vault approvals, and a notable crypto treasury initiative with Greenlane Holdings. The community is sharply divided, with bulls highlighting its growing TVL and unique PoL model for potential gains, while bears voice concerns over recent token unlocks and selling pressure.

Insight Enterprises, Inc. engages in the provision of information technology (IT) hardware, software, and services. The firm offers supply chain optimization, connected workforce, cloud and data center transformation, and digital innovation. It operates through the following geographical segments: North America, Europe, Middle East, and Africa (EMEA), and Asia-Pacific (APAC). The company was founded by Eric J. Crown and Timothy A. Crown in 1988 and is headquartered in Chandler, AZ.

Insight Enterprises Inc.

Insight Enterprises is trending following its Q4 earnings recap, which revealed strong GAAP EPS growth and a positive outlook, complemented by strategic moves like a new AWS collaboration and the Sekuro cybersecurity acquisition. The community remains divided, discussing the company's strong positioning in digital transformation and cloud against some revenue misses, fueling active debate and technical plays including short squeeze speculation.

Autodesk, Inc. engages in the design of software and services. Its products include AutoCAD, BIM Collaborate Pro, Revit, Civil 3D, Fusion 360, InfraWorks, Inventor, Maya, PlanGrid, Revit, Shotgun, and 3ds Max. The firm also offers product development and manufacturing software, which provides manufacturers in the automotive, transportation, industrial machinery, consumer products, and building product industries with digital design, engineering, and production solutions. The firm is also involved in digital media and entertainment, which consists of tools for digital sculpting, modeling, animation, effects, rendering, and compositing for design visualization, visual effects, and games production. The company was founded by John Walker in April 1982 and is headquartered in San Francisco, CA.

Autodesk Inc.

Autodesk is trending as activist investor Starboard Value has taken a significant stake, pushing for board and management changes while suing to delay the annual meeting, which is fueling community debate over the company's accounting practices and its strategy for AI-driven growth in the design software sector.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Celldex Therapeutics is trending following recent positive Phase 2 data for its lead asset barzolvolimab in chronic urticaria, which showcases strong efficacy and high complete response rates and has led to bullish analyst price targets. However, the community is debating whether mechanism-related side effects and long approval timelines will temper its 'blockbuster' potential, contributing to recent share price volatility.

Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. Thermo Fisher Scientific serves customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company’s global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increases its depth of capabilities across its broad portfolio of innovative products and services and leverages its extensive global channels to address customers’ needs. The company does this through organic investments in research and development, capacity and capabilities and through acquisitions. The company’s goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company’s history roots back to the year 1956 when the business was first established. Thermo Fisher Scientific was formed in 2006 from the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, MA.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is trending as the market digests its recent Q4 earnings beat, which highlighted solid sales growth and operational execution amidst some lingering margin pressures. The community is also actively discussing strategic moves, including a significant acquisition and a new R&D partnership for cancer screening, alongside a substantial share repurchase authorization signaling confidence in future growth.

CSX Corp. engages in the provision of rail-based freight transportation services. Its services include rail service, the transport of intermodal containers and trailers, rail-to-truck transfers and bulk commodity operations. It operates through Rail and Trucking segments. The Rail segment provides rail-based transportation services including traditional rail service and the transport of intermodal containers. The Trucking segment consists of Quality Carriers. The company was founded in 1827 and is headquartered in Jacksonville, FL.

CSX Corp.

CSX is trending due to heightened speculation around potential strategic options, including a merger or takeover, amplified by reports that the company is engaging with Goldman Sachs to explore opportunities. This buzz comes amid significant consolidation within the rail industry and a recent leadership change, with the community also noting the company's large fleet modernization investment.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting overwhelmingly positive Phase 2 trial results for sonelokimab in axSpA, with the community celebrating its "disease-modifying" potential and best-in-class efficacy, leading to widespread speculation about a significant re-rating, potential buyout, and high anticipation for its upcoming investor day.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Akamai Technologies (NASDAQ:AKAM) Price Target Raised to $110.00 at Citigroup

Citigroup lifted their target price on shares of Akamai Technologies from $103.00 to $110.00 and gave the stock a "neutral" rating in a research report on Friday...

Vanguard Group Inc. Sells 51,273 Shares of Akamai Technologies, Inc. $AKAM

Vanguard Group Inc. decreased its stake in Akamai Technologies, Inc. (NASDAQ:AKAM - Free Report) by 0.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities...

Stocks making the biggest moves midday: Amazon, Shopify, Grail, Akamai Technologies, Walmart & more

Here are some of the stocks making the biggest moves in midday trading...

UBS Group Issues Positive Forecast for Akamai Technologies (NASDAQ:AKAM) Stock Price

UBS Group lifted their target price on Akamai Technologies from $90.00 to $110.00 and gave the company a "neutral" rating in a report on Friday...

Akamai Tumbles 11% Despite Q4 Beat As 2026 Outlook Disappoints

Akamai Technologies shares fall after the company reported q4 results and issued FY26 adjusted earnings per share guidance below estimates.read more...

Akamai Technologies (NASDAQ:AKAM) Shares Gap Down Following Analyst Downgrade

Akamai Technologies (NASDAQ:AKAM) Shares Gap Down on Analyst Downgrade...

Skandinaviska Enskilda Banken AB publ Acquires 31,498 Shares of Akamai Technologies, Inc. $AKAM

Skandinaviska Enskilda Banken AB publ grew its holdings in Akamai Technologies, Inc. (NASDAQ:AKAM - Free Report) by 94.5% in the 3rd quarter, according to its most recent disclosure with the...

Royal Bank Of Canada Forecasts Strong Price Appreciation for Akamai Technologies (NASDAQ:AKAM) Stock

Royal Bank Of Canada lifted their target price on Akamai Technologies from $90.00 to $100.00 and gave the stock a "sector perform" rating in a research report on Friday...

Craig Hallum Raises Akamai Technologies (NASDAQ:AKAM) Price Target to $100.00

Craig Hallum lifted their price objective on Akamai Technologies from $90.00 to $100.00 and gave the stock a "hold" rating in a research report on Friday...

Akamai Technologies (NASDAQ:AKAM) Given New $76.00 Price Target at The Goldman Sachs Group

The Goldman Sachs Group lifted their target price on Akamai Technologies from $69.00 to $76.00 and gave the company a "sell" rating in a research report on Friday...

Akamai Technologies, Inc. engages in the provision of cloud services for delivering, optimizing, and securing content and business applications over the Internet. Its products include security, web performance, media delivery, and network operator. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

AKAM
Akamai Technologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AKAM News

AKAMAkamai Technologies Inc